MB-097
- Generic Name
- MB-097
A Phase 1b Trial to Evaluate Safety of MB097 in Combination with Pembrolizumab in Melanoma Patients
Phase 1
Recruiting
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Microbiotica Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06540391
- Locations
- 🇫🇷
Centre Georges Francois Leclerc, Dijon, France
🇫🇷CHU de Lille - Hopital Claude Huriez, Lille, France
🇫🇷Centre Leon Berard, Lyon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath